Heptech Biomedical Technology Co.

What Heptech Biomedical Technology Co. does

Heptech Biomedical Technology Co. (HepaiTech, 海湃泰克（北京）生物医药科技有限公司) is a privately held Beijing-based biopharmaceutical company founded in late 2019. The company specializes in small-molecule drug discovery and pre-clinical research targeting G-protein coupled receptors (GPCRs), with three core pipeline programs: an MrgprX4 antagonist for metabolic disorder-induced systemic pruritus, an MrgprX2 antagonist for autoimmune and inflammatory diseases, and an M receptor agonist for schizophrenia and other neurological conditions. Its lead asset, HEP-50768, received FDA IND approval in August 2025 and NMPA IND approval in September 2025, advancing the company into clinical-stage development with dual China/US regulatory pathways.

Name

Heptech Biomedical Technology Co.

Legal name

海湃泰克（北京）生物医药科技有限公司

Website

https://hepaitech.com

Company type

Private

Founded year

2019

Operating status

Operating

Short description

Heptech Biomedical Technology Co. (HepaiTech) is a Beijing-based private biotech founded in 2019 that develops small-molecule GPCR-targeted drugs for chronic pruritus, autoimmune inflammation, and schizophrenia, with lead asset HEP-50768 holding FDA and NMPA IND approvals.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• GPCR drug discovery
• Innovative drug development
• Anti-pruritus therapeutics
• Autoimmune drug pipeline
• Psychiatric small molecules

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Drug Licensing and Royalties: As a pre-revenue biotech company in clinical stage, Heptech's primary revenue model is expected to be through out-licensing of drug candidates to global pharmaceutical partners, milestone payments, and future royalty streams from approved drugs. The company has a track record of licensing deals, having previously licensed a drug to Roche.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Heptech Biomedical Technology Co. is a clinical-stage biopharmaceutical company that discovers and develops innovative small-molecule drugs targeting G-protein coupled receptors (GPCR). Its portfolio includes three pipeline programs — MrgprX4 antagonist for chronic pruritus, MrgprX2 antagonist for autoimmune/inflammatory diseases, and M receptor agonist for schizophrenia — with lead candidate HEP-50768 cleared by both FDA and NMPA for clinical trials in 2025.

Product overview

海湃泰克（北京）生物医药科技有限公司是一家致力于创新药物研发的生物科技企业，聚焦GPCR靶点开发，专注于代谢紊乱造成的系统性瘙痒、免疫炎症、精神分裂症等神经性疾病的创新药物研发。公司已建立三大核心产品管线：管线一为抗瘙痒药物-MrgprX4拮抗剂，管线二为自免类药物-MrgprX2拮抗剂，管线三为精神类药物-M受体激动剂。其中，HEP-50768片是公司进展最快的候选药物，已获得中国NMPA和美国FDA的IND批准，标志着公司创新药研发进入临床阶段。

Differentiator

Problem solved

Functional benefit

Products and services

• Pipeline 1: Anti-pruritus drug — MrgprX4 antagonist Small-molecule MrgprX4 receptor antagonist being developed for the treatment of systemic pruritus (itching) caused by metabolic disorders.
• Pipeline 2: Autoimmune drug — MrgprX2 antagonist Small-molecule MrgprX2 receptor antagonist being developed for immune-inflammatory and autoimmune conditions.
• Pipeline 3: Psychiatric drug — M receptor agonist Small-molecule M receptor agonist being developed for schizophrenia and other neurological/psychiatric diseases.
• HEP-50768 tablet Heptech's lead clinical-stage GPCR-targeted innovative drug candidate; cleared by both U.S. FDA (IND, August 2025) and China NMPA (IND, September 2025) to enter clinical trials for indications including metabolic disorder-induced systemic pruritus, immune inflammation, and schizophrenia.

Quantifiable outcome

• HEP-50768 received NMPA IND approval in September 2025 and FDA IND approval in August 2025, enabling clinical development
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Septerna: A native GPCR drug discovery platform company pursuing multiple GPCR targets with novel small molecules — closely comparable to Heptech's GPCR-focused discovery engine and stage of development.
• Escient Pharmaceuticals: GPCR-focused biotech developing MRGPRX2 (EP262) and MRGPRX4 (EP547) antagonists for pruritus and inflammatory diseases — directly overlapping Heptech's lead two programs in target, indication, and modality. Acquired by Incyte in 2024, providing a strong comparable for pipeline value.

Others

• Galderma: Dermatology-focused pharma with a significant pruritus franchise (e.g., nemolizumab) — comparable as a downstream commercial player and potential partner for Heptech's MrgprX4 anti-pruritus program.

Emerging players

• Rapport Therapeutics: Clinical-stage CNS biotech focused on neuroscience targets including receptor-based mechanisms — comparable as a similarly-staged emerging player in CNS drug discovery with comparable program structure.
• Praxis Precision Medicines: Clinical-stage CNS biotech developing therapies for neurological and psychiatric disorders — comparable in indication overlap (schizophrenia/psychiatric) and as a similarly-sized emerging CNS player.
• Neumora Therapeutics: Clinical-stage neuropsychiatric and neurodegenerative disease biotech with multiple CNS programs in early development — comparable stage, therapeutic area focus, and platform-replenishment model to Heptech.
• LB Pharmaceuticals: Clinical-stage CNS biotech developing muscarinic receptor agonists for schizophrenia — directly comparable mechanism to Heptech's M receptor agonist program and a similar indication overlap with HEP-50768's CNS franchise.

Broad incumbents

• Karuna Therapeutics (now Bristol Myers Squibb): Developed Cobenfy (xanomeline/trospium), the first muscarinic-agonist schizophrenia therapy approved in 2024 and acquired by BMS for ~$14B — sets the commercial benchmark for Heptech's M-receptor schizophrenia program.
• Neurocrine Biosciences: Established CNS-focused biotech developing NBI-1117568, a selective M4 muscarinic agonist for schizophrenia — a direct mechanistic comparator to Heptech's M receptor program and a validation point for the muscarinic schizophrenia thesis.
• Cerevel Therapeutics (now AbbVie): CNS-focused biotech with multiple neuroscience programs including muscarinic and dopamine receptor modulators — comparable as a CNS biotech comparable in indication and target class; acquired by AbbVie for $8.7B in 2024.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Heptech Biomedical Technology Co.